Please provide your email address to receive an email when new articles are posted on . The Foundation to Advance Vascular Cures has launched a new virtual educational resource directed at medical ...
The European Commission (EC) has approved a regimen of rivaroxaban (Xarelto, Bayer) 2.5 mg twice daily plus acetylsalicylic acid (ASA) 75 to 100 mg once daily for the prevention of atherothrombotic ...
During the month of May, the Cartridge and Propellant Actuated Device (CAD/PAD) Joint Program supported two workshops sponsored by NAVAIR's Program Management Air (PMA) 201 at the College of Southern ...
"We have shown that a younger age at diagnosis of PAD (low ABI or calcified arteries) is associated with increased risk of cardiovascular events. This is powerful information for both primary care ...
Johnson & Johnson and Bayer’s wide-spanning VOYAGER PAD study continues to be a gold mine for proving its Xarelto’s worth in several subsets of patients with peripheral artery disease (PAD). New ...
COMPASS open label extension study results support the long-term use of XARELTO ® plus aspirin for vascular protection in patients with chronic CAD and/or PAD XATOA registry provides further evidence ...
In April, an ejection seat manufacturer officially notified the Naval Surface Warfare Center Indian Head Division (NSWC IHD) Cartridge Actuated Devices/Propellant Actuated Devices (CAD/PAD) Joint ...
Consider total event risk—not just first events—say the investigators of a recent report, which found more than 60 total cardiovascular and limb events occurring per 100 patients through 3 years of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results